Skip to main content

Table 4 Concurrent Chemotherapy-Related Adverse Events

From: Efficacy and safety of concurrent anti-Cancer and anti-tuberculosis chemotherapy in Cancer patients with active Mycobacterium tuberculosis: a retrospective study

NCI-CTCa (Grade) Patients
All LC CRC Other
(n = 28) (n = 13b) (n = 10) (n = 5)
Adverse event 1–2 ≥3 1–2 ≥3 1–2 ≥3 1–2 ≥3
Hematological toxicity, number of cases
 Leukocytopenia 7 8 4 6 3 1 2 1
 Neutropenia 5 14 1 9 2 3 2 2
 Anemia 20 2 9 2 8 0 3 0
 Thrombocytopenia 3 3 1 2 1 1 1 0
 Lymphopenia 13 10 4 8* 7 1 2 1
Non-hematological toxicity, number of cases
 AST/ALT elevation 12 0 4 0 6 0 2 0
 Interstitial pneumonitis 0 1c 0 1c 0 0 0 0
 Colitis 0 1d 0 0 0 0 0 1d
 Anaphylaxis 0 2e 0 0 0 2e 0 0
 Hemorrhage 1f 1g 1f 0 0 1g 0 0
  1. Abbreviations CRC colorectal cancer, LC lung cancer
  2. aNCI-CTC: National Cancer Institute Common Toxicity Criteria
  3. bIn two of 15 patients, laboratory data was lost
  4. cDeath caused by pemetrexed-induced pneumonitis
  5. dPseudomembranous colitis due to Clostridium difficile infection
  6. eOxaliplatin- and cetuximab-induced anaphylaxis
  7. fNasal bleeding
  8. gHemoptysis
  9. *: P < 0.005